Drugs / Instant MSC Product accompanying Autologous Chondron Transplantation
Instant MSC Product accompanying Autologous Chondron Transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04236739 | Jul 2019 → Sep 2025 | articular cartilage disorder | R.J.H. Custers | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Instant MSC Product accompanying Autologous Chondron Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04236739 ↗ |
| Modality | Cell therapy | “IMPACT is designed as a one-stage cell-based regenerative therapy for isolated articular cartilage lesions.” NCT04236739 ↗ |
| Route | Other | “Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.” NCT04236739 ↗ |